Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults.

Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL.

Hum Vaccin. 2007 Sep-Oct;3(5):205-11. Epub 2007 May 18.

PMID:
17881903
2.

Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human lgG antibodies to anthrax lethal factor antigen.

Selinsky CL, Whitlow VD, Smith LR, Kaslow DC, Horton HM.

Biologicals. 2007 Apr;35(2):123-9. Epub 2006 Oct 30.

PMID:
17071101
3.

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.

Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M.

Vaccine. 2006 Aug 14;24(33-34):5950-9. Epub 2006 Jun 5.

PMID:
16797805
4.

Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.

Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT Jr.

Vaccine. 2006 Apr 24;24(17):3654-60. Epub 2006 Feb 9.

PMID:
16497418
5.

II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential.

Vilalta A, Mahajan RK, Hartikka J, Leamy V, Martin T, Rusalov D, Bozoukova V, Lalor P, Hall K, Kaslow DC, Rolland A.

Hum Gene Ther. 2005 Oct;16(10):1151-6.

PMID:
16218776
6.

Development of anthrax DNA vaccines.

Ferrari ME, Hermanson G, Rolland A.

Curr Opin Mol Ther. 2004 Oct;6(5):506-12. Review.

PMID:
15537052
7.

Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax.

Quinn CP, Dull PM, Semenova V, Li H, Crotty S, Taylor TH, Steward-Clark E, Stamey KL, Schmidt DS, Stinson KW, Freeman AE, Elie CM, Martin SK, Greene C, Aubert RD, Glidewell J, Perkins BA, Ahmed R, Stephens DS.

J Infect Dis. 2004 Oct 1;190(7):1228-36. Epub 2004 Aug 30.

PMID:
15346332
8.

A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, Hobart P.

Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13601-6. Epub 2004 Sep 1.

9.

Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.

Quinn CP, Semenova VA, Elie CM, Romero-Steiner S, Greene C, Li H, Stamey K, Steward-Clark E, Schmidt DS, Mothershed E, Pruckler J, Schwartz S, Benson RF, Helsel LO, Holder PF, Johnson SE, Kellum M, Messmer T, Thacker WL, Besser L, Plikaytis BD, Taylor TH Jr, Freeman AE, Wallace KJ, Dull P, Sejvar J, Bruce E, Moreno R, Schuchat A, Lingappa JR, Martin SK, Walls J, Bronsdon M, Carlone GM, Bajani-Ari M, Ashford DA, Stephens DS, Perkins BA.

Emerg Infect Dis. 2002 Oct;8(10):1103-10.

10.

Anthrax as a biological weapon, 2002: updated recommendations for management.

Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K; Working Group on Civilian Biodefense.

JAMA. 2002 May 1;287(17):2236-52. Review. Erratum in: JAMA 2002 Oct 16;288(15):1849.

PMID:
11980524
11.

Prevention of inhalational anthrax in the U.S. outbreak.

Brookmeyer R, Blades N.

Science. 2002 Mar 8;295(5561):1861. No abstract available.

12.

Anthrax toxin.

Bhatnagar R, Batra S.

Crit Rev Microbiol. 2001;27(3):167-200. Review.

PMID:
11596878
13.

Anthrax.

Mock M, Fouet A.

Annu Rev Microbiol. 2001;55:647-71. Review.

PMID:
11544370
14.

In vitro correlate of immunity in a rabbit model of inhalational anthrax.

Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, Gibbs P, Dertzbaugh M, Friedlander AM.

Vaccine. 2001 Sep 14;19(32):4768-73.

PMID:
11535328
15.

Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin.

Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, Friedlander AM.

Vaccine. 2001 Apr 30;19(23-24):3241-7. Erratum in: Vaccine 2001 Nov 12;20(3-4):635.

PMID:
11312020
16.
17.

Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.

McBride BW, Mogg A, Telfer JL, Lever MS, Miller J, Turnbull PC, Baillie L.

Vaccine. 1998 May;16(8):810-7.

PMID:
9627938
18.

Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

Little SF, Ivins BE, Fellows PF, Friedlander AM.

Infect Immun. 1997 Dec;65(12):5171-5.

19.

The Sverdlovsk anthrax outbreak of 1979.

Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O.

Science. 1994 Nov 18;266(5188):1202-8.

PMID:
7973702

Supplemental Content

Support Center